VEXAS syndrome is a rare adult-onset hematologic and auto inflammatory disease caused by acquired somatic mutations in the UBA1 gene within bone marrow stem cells. Unlike inherited genetic disorders, the mutation develops later in life within the body’s blood-forming cells, leading to a combination of hematologic abnormalities and widespread systemic inflammation. Patients may experience blood disorders such as anemia, cytopenias, and bone marrow dysfunction, alongside inflammatory symptoms affecting multiple organs and tissues. Because the underlying defect originates in the hematopoietic system, VEXAS is appropriately classified as a hematologic disease.
Use Group: Hematologic Diseases:
0.03, 0.37, 0.97, 2.75, 81.5, 172.5, 396.5, 475.29, 533.63, 876.29
Use the Rife Digital Professional V3 on the Hematologic Diseases group for the control of inflammation and related complications, and perhaps eliminate the source of the disease.
Current Medical Data on treatments:
The disease is caused by an acquired mutation in the bone marrow’s blood-forming stem cells. Because the underlying problem originates in these abnormal cells, a bone marrow (stem cell) transplant may, in some cases, remove the source of the disease and provide a potentially curative treatment. This makes VEXAS unusual, as many genetic disorders can only have their symptoms managed, whereas VEXAS may be treated at its underlying cause through stem cell transplantation.
